Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GCGR | P47871 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.42 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502553 | 0.92 | SMO (0.51) | — | |
| SCHEMBL6489227 | 0.87 | CTNNB1 (0.48) | L3MBTL1RAB9ANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL6489905 | 0.85 | PPARG (0.46) | L3MBTL1RAB9ANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL6490419 | 0.85 | L3MBTL1 (0.46) | L3MBTL1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL6501179 | 0.85 | SYK (0.47) | L3MBTL1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL6490832 | 0.84 | PLG (0.45) | L3MBTL1RAB9ANPC1KMT2AALOX15 | |
| SCHEMBL6489180 | 0.83 | L3MBTL1 (0.44) | L3MBTL1RAB9ANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL6498569 | 0.83 | ALOX15 (0.44) | L3MBTL1RAB9ANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL6498069 | 0.83 | HDAC7 (0.49) | L3MBTL1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL6488546 | 0.82 | CTNNB1 (0.54) | L3MBTL1RAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | L3MBTL1 2276/4885RAB9A 4382/4885NPC1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.